Skip to content

Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With NAFLD

Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized Control Trials

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05909631
Acronym
BJ
Enrollment
180
Registered
2023-06-18
Start date
2023-01-10
Completion date
2023-04-11
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD, Non-alcoholic Fatty Liver Disease

Keywords

Mediterranean diet, Beetroot juice, nonalcoholic fatty liver

Brief summary

The goal of this clinical trial study is to investigate comparing Effects of Beetroot juice and Mediterranean diet on Liver Enzymes and Sonographic appearance in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) The main question\[s\] it aims to answer are: 1. Beetroot juice has role in reduce Liver Enzymes 2. Mediterranean diet has role in reduce Liver Enzymes

Detailed description

Patients with NAFLD were identified and enrolled for this research at the PAR hospital in the Kurdistan Region of Iraq. For 12 weeks, for the group members who were receiving the MeD, we recommended consuming Mediterranean foods like fish, poultry, sources of omega-3, vegetables and colored fruits, legumes and nuts, and low-fat goods while avoiding inflammatory foods like high-fat foods, processed meats, fast food, simple sugars, chips, and soft drinks. At baseline, the participants' demographic and anthropometric information, including as gender, age, weight, height, smoking status, location of residence, and physical activity, were recorded.

Interventions

OTHERBeetroot juice

250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.

OTHERplacebo

250 ml of a placebo

OTHERMediterranean diet alone (MeD)

Mediterranean diet alone (MeD)

COMBINATION_PRODUCTMediterranean diet with beet juice (BJ+MeD)

Mediterranean diet with beet juice (BJ+MeD).

Sponsors

Sulaimany Polytechnic university
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Statical analyser

Intervention model description

The participants were split into four groups: control, Mediterranean diet with beet juice (BJ+MeD), Mediterranean diet alone (MeD) and beetroot juice (BJ). The Mediterranean diet included fruits, vegetables, fish, poultry, and other lean meats (without skin), sources of omega-3 fatty acids, nuts, and legumes. Beetroot juice had 250 mg of beetroot.

Eligibility

Sex/Gender
ALL
Age
19 Years to 73 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients had to be between the ages of 19 and 73, and they had to have NAFLD as their main diagnosis. 2. For a NAFLD diagnosis, ultrasound proof of fatty liver (stage I or above) and an elevated level of liver enzymes were required.

Exclusion criteria

1. history of diseases like cardiovascular, liver, chronic hepatitis C, and kidney disease 2. supplement use within the previous six months; hormone therapy; use of drugs like amiodarone, methotrexate, and corticosteroids 3. cases of starvation or inadequate nutrition; pregnancy; metabolic disorders like Wilson disease and glycogen storage disease; a history of liver irradiation

Design outcomes

Primary

MeasureTime frameDescription
Beetroot juice has role in reduce liver enzymes12 weeksBeetroot juice was given for 12 weeks and has role in reduce Serum Bilirubin, alkaline phosphatase (ALP), alanine transaminase (ALT), and liver enzyme was measured by blood sampling tests.

Secondary

MeasureTime frameDescription
Mediterranean diet contributes to lower liver enzyme levels.12 weeksMediterranean diet was given for 12 weeks and has role in reduce Serum Bilirubin, alkaline phosphatase (ALP), alanine transaminase (ALT), and liver enzyme was measured by blood sampling tests.

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026